Tokyo Stock Exchange

THine Unveils Its Advanced Interface Technology “V-by-One® HS plus,” Suitable for Achieving Energy Efficiency of Televisions

Retrieved on:

Friday, April 21, 2023

Semiconductor, Technology, Manufacturing, Audio, Video, Other Manufacturing, Hardware, Thou, Tokyo Stock Exchange, Electronics, Multimedia, LCD, THine Electronics, HS, OLED, LSI, Television

“V-by-One® HS plus” technology is suitable for achieving required energy efficiency of televisions and displays, corresponding to today’s requirements of higher resolution and refresh rate.

Key Points:

“V-by-One® HS plus” technology is suitable for achieving required energy efficiency of televisions and displays, corresponding to today’s requirements of higher resolution and refresh rate.
THine will start providing “V-by-One® HS plus Standard” to its valuable licensees since June 2023, replacing today’s de facto standard.
“V-by-One® HS plus Standard” provided by THine has two modes: 1) “HS plus Mode” with data rate of 8Gbps/lane and 2) “HS Mode” compatible to today’s de facto standard technology, V-by-One® HS.
Since “V-by-One® HS plus Standard” has such two modes, current V-by-One® HS will end to be replaced and new users will be supported by “V-by-One® HS plus Standard.” This advanced technology follows V-by-One® HS Standard, including basic protocols, design concept, so that users have little hurdles in switching from V-by-One® HS.

Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting

Retrieved on:

Wednesday, April 19, 2023

The abstracts present preclinical data from the Company’s LAMA2 Congenital Muscular Dystrophy (LAMA2-CMD).

Key Points:

The abstracts present preclinical data from the Company’s LAMA2 Congenital Muscular Dystrophy (LAMA2-CMD).
At ASGCT, we will present preclinical data from MDL-101 validating the efficacy and safety of our differentiated therapeutic strategy utilizing our CRISPR-GNDM® technology for the previously difficult-to-treat LAMA2-CMD.
"Our proprietary and world-first CRISPR-based epigenetic editing technology, CRISPR-GNDM®, controls the expression levels of disease-causing genes and provides a disease-modifying treatment for genetic disorders,” said Haru Morita, CEO of Modalis.
Title: Advancing Epigenetic Editing with CRISPR-GNDM: Novel Muscle-Tropic AAV Vectors Deliver Promising Single-Dose Treatment for LAMA2-CMD

Nidec Copal Electronics Completes the Acquisition of the Shares of Midori Precisions

Retrieved on:

Friday, March 31, 2023

Engineering, Consumer Electronics, Technology, Manufacturing, Other Manufacturing, Hardware, Machinery, Disclosure, Electronics, Tokyo Stock Exchange

If necessary, the Company will make additional disclosure on a timely basis in accordance with the rules of the Tokyo Stock Exchange upon determination of further details.

Key Points:

If necessary, the Company will make additional disclosure on a timely basis in accordance with the rules of the Tokyo Stock Exchange upon determination of further details.
This press release contains forward-looking statements regarding the intent, belief, strategy, plans or expectations of the Nidec Group or other parties.
Such forward-looking statements are not guarantees of future performance or events and involve risks and uncertainties.
On April 1, 2023, Nidec Copal Electronics will be renamed Nidec Components Corporation.

Monstarlab Holdings Inc. Becomes Independent Publicly Traded Company, Begins Trading on Tokyo Stock Exchange

Retrieved on:

Tuesday, March 28, 2023

Monstarlab Holdings Inc. (TYO: 5255), a global digital transformation consultancy leader, specializing in end-to-end enterprise-level digital solutions, celebrated its debut as a public company today.

Key Points:

Monstarlab Holdings Inc. (TYO: 5255), a global digital transformation consultancy leader, specializing in end-to-end enterprise-level digital solutions, celebrated its debut as a public company today.
CEO, Hiroki Inagawa, joined senior leadership, company employees and investors to ring the Opening Bell at the Tokyo Stock Exchange Growth Market.
This announcement provides the springboard for further growth and enhances Monstarlab’s presence in the United States, Canada and Colombia.
View the full release here: https://www.businesswire.com/news/home/20230327005735/en/
CEO Hiroki Inagawa with the Monstarlab senior leadership team at the Tokyo Stock Exchange.

Mitch Lasky and Junghun Lee Appointed to Serve on Nexon’s Board of Directors

Retrieved on:

Friday, March 24, 2023

NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced that Junghun Lee and Mitchell (Mitch) Lasky were elected as directors of its board at the annual general meeting of shareholders held on March 24.

Key Points:

NEXON Co., Ltd. (Nexon) (3659.TO), a global leader in Virtual Worlds, today announced that Junghun Lee and Mitchell (Mitch) Lasky were elected as directors of its board at the annual general meeting of shareholders held on March 24.
In addition, three directors were reappointed to the board: Owen Mahoney, Shiro Uemura, and Patrick Söderlund.
Additionally, three members of the Audit and Supervisory Committee – Alexander Iosilevich, Satoshi Honda and Shiro Kunia – will serve the second year of their terms.
Junghun Lee is a deeply experienced leader in the global game industry.

Fujitsu named a "Nadeshiko Brand" company for promoting women's success

Retrieved on:

Wednesday, March 22, 2023

Workplace, Tokyo Stock Exchange, DE, METI, Culture, TSE, Nursing, Fujitsu

Starting this fiscal year, METI and the TSE revamped the content of the Nadeshiko Brand survey, with significant changes to selection criteria and evaluation process, to further accelerate companies' efforts to promote women's success in the workplace.

Key Points:

Starting this fiscal year, METI and the TSE revamped the content of the Nadeshiko Brand survey, with significant changes to selection criteria and evaluation process, to further accelerate companies' efforts to promote women's success in the workplace.
Fujitsu represents the first company to be named a Nadeshiko Brand enterprise after these changes.
Fujitsu has been actively promoting women's success in the workplace as one of its management objectives.
Moving forward, Fujitsu will continue its efforts to advance DE&I and gender diversity, including activities to promote women's success in the workplace.

Canadian Solar Reports Fourth Quarter and Full Year 2022 Results

Retrieved on:

Tuesday, March 21, 2023

GUELPH, ON, March 21, 2023 /PRNewswire/ -- Canadian Solar Inc. ("Canadian Solar" or the "Company") (NASDAQ: CSIQ) today announced financial results for the fourth quarter and full year ended December 31, 2022.

Key Points:

GUELPH, ON, March 21, 2023 /PRNewswire/ -- Canadian Solar Inc. ("Canadian Solar" or the "Company") (NASDAQ: CSIQ) today announced financial results for the fourth quarter and full year ended December 31, 2022.
Depreciation and amortization charges in the fourth quarter of 2022 were $50 million, compared to $56 million in the third quarter of 2022 and $84 million in the fourth quarter of 2021.
Total project assets at the end of the fourth quarter of 2022 were $824 million, compared to $911 million at the end of the third quarter of 2022.
The net value of solar power systems at the end of the fourth quarter of 2022 were $365 million, compared to $101 million at the end of the third quarter of 2022.

Sosei Heptares Announces Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market

Retrieved on:

Wednesday, March 15, 2023

Tokyo Stock Exchange, Nordic Growth Market, Patient, TSE, GPCR, Growth, Acceleration, Pharmaceutical industry, Fine chemical, Video game, Asset management

Tokyo, Japan and Cambridge, UK, 15 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, today announces it has changed the market on which the Company's shares are listed on the Tokyo Stock Exchange, Inc. (“TSE”) from the Growth Market segment to the Prime Market segment, effective today.

Key Points:

Tokyo, Japan and Cambridge, UK, 15 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, today announces it has changed the market on which the Company's shares are listed on the Tokyo Stock Exchange, Inc. (“TSE”) from the Growth Market segment to the Prime Market segment, effective today.
Chris Cargill, President & CEO of Sosei Heptares, commented: “We believe that this move to TSE Prime is a key milestone in our vision to become one of Japan’s leading global biopharmaceutical champions.
This will result from a deepening and broadening of its shareholder base to reflect the global nature of the business.
For more details regarding the change of Sosei Heptares’ listing to the Prime Market segment, please refer to the Japan Exchange Group’s website https://www.jpx.co.jp/english/
In its full year 2022 results presentation (held on 14 February 2023), Sosei Group’s leadership set out a clear strategy to leverage the Company’s proprietary platform, pipeline and R&D expertise to grow the business internationally and in Japan.

Nidec Executes Stock Transfer Agreement on Nidec Copal Electronics’ Acquisition of Midori Precisions

Retrieved on:

Wednesday, March 15, 2023

Engineering, Technology, Manufacturing, Other Manufacturing, Machinery, Hardware, Disclosure, Stock, Tokyo Stock Exchange, Electronics

Having joined the Nidec Group in 1998, Nidec Copal Electronics is focused on its sensing business at present, actively engaging in the transformation of its business portfolio and entry into growth markets.

Key Points:

Having joined the Nidec Group in 1998, Nidec Copal Electronics is focused on its sensing business at present, actively engaging in the transformation of its business portfolio and entry into growth markets.
With no overlaps in the potentiometer and encoder product lineup between them, Midori Precisions and Nidec Copal Electronics will be able to generate synergies easily with each other, and expand sales together.
Not only will the Stock Acquisition enable the use of Midori Precisions’ technological strength and Nidec Copal Electronics’ production and manufacturing technologies and global sales channels to create synergies, it will ensure investment in Midori Precisions in a timely and appropriate manner.
The Stock Acquisition is expected to have no significant impact on the Company’s consolidated financial performance for this fiscal year ending March 31, 2023.

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Retrieved on:

Thursday, March 9, 2023

Code, MCM, Mothers (Tokyo Stock Exchange), Biomedical Advanced Research and Development Authority, Tokyo Stock Exchange, Development, Administration, Acute respiratory distress syndrome, ASPR, BARDA, Human services, White lung, Chlorine, United States Department of Health and Human Services, ALI, Rare-earth element, Medical device

LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Key Points:

LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
The contract was amended to extend the period of performance until May 31, 2023.
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50121C00022.